Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002787 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
A Phase 1 study, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00002787: Completed Phase 1 study, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
NCT00002787 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002787, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor. There is no guarantee or promise that this procedure will be successful
Primary Outcome
Descriptive statistics will be used to summarize changes from baseline in clinical laboratory parameters for each cohort.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL aldesleukin
- BIOLOGICAL sargramostim
- BIOLOGICAL autologous immunoglobulin idiotype-KLH conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 1996-03 |
| Phase | Phase 1 |
Sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium4 total trials
What the finished NCT00002787 record still lists
NCT00002787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00002787 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002787 about?
NCT00002787 is a clinical study titled "Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation". The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor. There is no guarantee or promise that this procedure will be successful
What is the current status of trial NCT00002787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 1996-03.
What interventions are being tested in trial NCT00002787?
The interventions under investigation include: laboratory biomarker analysis (OTHER), aldesleukin (BIOLOGICAL), sargramostim (BIOLOGICAL), autologous immunoglobulin idiotype-KLH conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002787?
This trial is sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002787's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia